Kornimate/medical-research-clean huggingface dataset:
nerve burial for preventing neuralgia after total knee arthroplasty

Conditions: Neuralgia; Osteoarthritis of the Knee

Summary: this is a randomized study investigating whether identification, ligation, and burial of superficial branches of the saphenous nerve crossing the surgical field during total knee arthroplasty reduces the rate of post-operative anterior knee pain and neuralgia compared to standard total knee arthroplasty.

anterior knee pain is common after total knee arthroplasty. the incision necessarily travels through the path of a cutaneous nerve - branches of the saphenous nerve. historically, no effort has been made to separate these branches and bury them away from the surgical scar. it has been noted that some patients develop a painful neuroma, that once resected results in a pain free knee. investigators are trying to study if identification, ligation, and proper burial of the nerve can prevent the development of neuralgia compared to the typical surgical approach which ignores the nerve branches completely.

Eligibility criteria:
inclusion criteria: * must have symptomatic knee osteoarthritis under consideration for total knee arthroplasty * must be willing to undergo randomization exclusion criteria: * age \ 80 years * known pre-operative diagnosis of neuralgia, complex regional pain syndrome, or neuropathy, about the operative lower extremity * known pre-operative psychiatric disorder requiring medication * previous surgery about the operative knee * bmi \> 40 kg/m2 (potential increased risk of soft tissue dissection through adipose) * ongoing pre-operative narcotic use in excess of 20 mg morphine equivalents per day for at least one month or pre-operative intravenous drug use (increased potential for complex regional pain syndrome and neuralgia, increased likelihood to require greater post-operative analgesia) * ongoing pre-operative use of neuropathic pain medications (gabapentin, pregabalin, amitriptyline, etc.) * medical comorbidities (american society of anesthesiologists grade \> 3 or deemed unfit by consulting internist) precluding elective tka * significant language barrier (reading comprehension less than 8th grade reading level) or mental condition precluding accurate self-assessment of knee pain or function. * severe medication allergies to permissible post-operative analgesics (acetaminophen, tramadol, oxycodone, oxycontin, dilaudid)

Keywords: total knee arthroplasty
evaluation of methods for the determination of chromogranin a in routine blood samples

Conditions: Neuroendocrine Carcinoma (Carcinoid)

Summary: the goal of this study is to compare several methods for measurement of chromogranin a in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors. further, in a subgroup, we will determine if taking a proton pump inhibitor affects chromogranin a levels.

patient group: patients with neuroendocrine tumors (active or inactive) healthy volunteers

Eligibility criteria:
patients: inclusion criteria: * having neuro-endocrine disease exclusion criteria: * age below 18 or above 70 years * prostate cancer * kidney failure (estimated gf \< 30 ml/min) * heart failure * chronic atrophic gastritis * pregnancy healthy subjects: inclusion criteria: * healthy exclusion criteria: * age below 18 or above 70 years * taking any chronic medication (except ocp) * prostate cancer * kidney failure (estimated gfr \< 30 ml/min) * heart failure * pheochromocytoma * islet cell tumors * medullary thyroid cancer * essential hypertension * neurofibromatosis * use of proton pump inhibitors * chronic atrophic gastritis * pregnancy

Keywords: chromogranin a neuroendocrine carcinoid proton pump inhibitor
effects of calcium supplementation on women in the curves for women program

Conditions: Diet Modification

Summary: the purpose of this study is to examine the effects of dietary calcium supplementation on weight loss, bone density, and markers of health and fitness in women participating in the curves exercise and diet program.

the curves international fitness and weight loss program has become a very popular means of promoting health and fitness among women. the program involves a 30-minute circuit training program and a weight management program involving periods of moderate caloric restriction (1,200 to 1,600 calories per day) followed by short periods of higher caloric intake (2,600 calories per day). the program is designed to promote a gradual reduction in body fat while increasing strength and muscle mass/tone. researchers in the exercise \& sport nutrition lab at texas a\&m university have conducted an extensive study on the effectiveness and safety of the curves fitness and diet program. results of this initial study have shown that the program promotes weight loss, improves markers of health, and improves fitness. however, we feel that the program may be even more effective with some additional nutritional interventions. calcium has been shown to slow bone loss and more recently has been found to help promote fat loss. if this is the case, supplementing the diet with calcium may promote greater benefits in women participating in the curves fitness/diet program. the purpose of this study is to examine the effect of dietary calcium supplementation on weight loss, bone density, and markers of health and fitness in women participating in the curves exercise and diet program.

Eligibility criteria:
inclusion criteria: * participant is female; * participant is post-menopausal; * participant is between the ages of 45 and 65; * participant is sedentary, overweight (bmi \> 27) and post-menopausal; exclusion criteria: * participant has any metabolic disorder including known electrolyte abnormalities, heart disease, arrhythmias, diabetes, or thyroid disease; * participant has a history of hypertension, hepatorenal, musculoskeletal, autoimmune or neurological disease; * participant is taking thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive or androgenic medications; * participant has taken ergogenic levels of nutritional supplements that may affect muscle mass (i.g., creatine, hmb, etc.), anabolic/catabolic hormone levels (i.e., androstenedione, dhea, etc.) or weight loss (i.e., ephedra, thermogenics, etc.) within three months prior to the start of the study; * participant is consistently taking 500 mg or more of a calcium supplement per day; * participant is receiving hormone replacement therapy (hrt); * participant is involved in a planned exercise program within 3 - 6 months prior to the start of the study; * participant has lost \> 20 lbs. within the last 3 - 6 months;

Keywords: calcium supplementation exercise intervention
impact of ctdna in cancer early detection and stas evaluation in patients with ggos

Conditions: Lung Cancer; Spreading of Tumor; Circulating Tumor Cell

Summary: the aim of the study is the early and non-invasive diagnosis of lung cancer in patients with pulmonary ground glass opacity. in particular, objective of the study is to evaluate the presence or absence of circulating tumor dna (ctdna) on the peripheral blood of patients with evidence of ground glass opacity(ggo) at ct scan and to evaluate the role that this can play in the diagnostic / therapeutic process. the ctdna evaluation will be performed at the first radiological finding and subsequently correlated with the malignancy of the lesion based on the radiological / histological criteria regularly used in international protocols. secondary objective is the correlation, in patients with malignant ggo undergoing surgical treatment, of the ctdna presence and tumor spread through the air spaces (stas), and its correlation with local relapses.


Eligibility criteria:
inclusion criteria: * age\> 18 years * radiological finding of pulmonary ground glass opacity * absence of solid or haematological tumor exclusion criteria: * radio / chemotherapy treatment for at least 6 months * patient unable to understand and express his consent to the study
cardiopulmonary bypass on mechanical power and postoperative pulmonary complications

Conditions: Postoperative Pulmonary Atelectasis; Pneumothorax; Pneumonia; Ards; Respiratory Failure

Summary: during cardiopulmonary bypass (cpb), oxygenation of the patient on the pump can be left completely under pump control, or the lungs can be ventilated with low tidal volume to reduce atelectasis. in recent years, the concept of mechanical power has been used to determine the extent of ventilator-related lung damage. this concept of mechanical power, by which the energy transferred by the ventilator to the lungs can be calculated, will be measured at certain intervals in cpb surgery patients on the pump and compared between the two groups. the investigators aimed to investigate the effect of two different ventilation methods on mechanical power and its relationship with postoperative pulmonary complications.

patients will be taken to the operating table after preoperative evaluation. routine monitoring and routine anesthesia method will be applied to the patient. access will be made through the radial artery for arterial catheterization. patients will be ventilated with 6-8 ml/kg tidal volume, 12-14 frequency/min, 5 positive end expiratory pressure(peep), 60% fraction of inspired oxygen(fio2) and oxygen saturation over 94. end tidal carbon dixide(co2) will be kept in the range of 32-37. after cardiac catheterizations are performed, the pump will be entered, and after all preparations are completed, an aortic cross-clamp will be placed and cardioplegic solution will be sent. after the patient enters the pump at full flow; group 1: non-ventilated patient group. here, patients will be placed in the cardiac bypass mode of the anesthesia machine. only 150 ml of free air flow will be provided and mechanical ventilation will be turned off. group 2: patients will continue to be ventilated at fio2: 40%, tv: 3 ml/kg, frequency 12 breaths/min, peep: 5 cm/h2o.

Eligibility criteria:
i̇nclusion criteria: * patients who will undergo elective cardiopulmonary bypass surgery and agree to participate in the study * patients who will undergo coronary or valve surgery * surgeries performed on a stopped heart * patients over 18 years exclusion criteria: * patients undergoing emergency cardiac surgery * patients who will undergo redo surgery * patients who will undergo total circulatory arrest surgery * patients in a state of preoperative shock * patients with acute and chronic hypoxemia (pao2 \<65mmhg, spo2 \<95 in room air) * patients followed with mechanical ventilation for 7 days before surgery * patients with bmi\>35 * patients with obstructive sleep apnea syndrome * patients with pulmonary artery pressure \>50 mmhg * patients with glomerular filtration rate \<30 ml/min
increasing availability and acceptability of circumcision in zambia

Conditions: HIV

Summary: this study proposes to balance supply and demand of male circumcision through a systematic scale-up of coordinated biomedical surgical and behavioral counseling services. the study will compare the combined biobehavioral sexual risk reduction intervention to the standard of care, which focuses exclusively on the provision of circumcision services alone, with the goal of optimizing both local and national hiv prevention efforts.


Eligibility criteria:
inclusion criteria: * hiv negative * uncircumcised male * 18+ years of age * able to understand and sign informed consent in english, bemba, or nyanja * have not requested male circumcision services at the time of or following vct * female partners of enrolled males are invited to participate exclusion criteria: * men seeking circumcision services are not eligible for this study * men with genital abnormalities requiring mc, e.g. balanitis (inflammation of the preputial skin), posthitis (inflammation of the glans penis; common in patients with diabetes), phimosis (scarring of the distal margins of the foreskin) resulting from chronic balanitis, paraphimosis (the inability to pull the retracted foreskin back over the glans) or diseases of the foreskin, including localized carcinoma are not eligible for this study * men with congenital or acquired penile abnormalities that require the preputial skin for generative repair, such as hypospadias (urethra exits from underside of penis) are not eligible to participate * participants unable to provide informed consent will not be eligible.

Keywords: hiv male circumcision sexual risk reduction stages of change
a prospective, randomized controlled study of cyclophosphamide, bevacizumab with or without envafolimab in recurrent epithelial ovarian cancer (eoc), fallopian tube cancer, and primary peritoneal cancer

Conditions: Epithelial Ovarian Cancer

Summary: the primary objective of this study is to evaluate the efficacy and safety of cyclophosphamide and bevacizumab in combination with envafolimab in the treatment of recurrent epithelial ovarian cancer (eoc), fallopian tube cancer, and primary peritoneal cancer.


Eligibility criteria:
inclusion criteria: * age 18-70 years histologically or pathologically confirmed epithelial ovarian cancer (eoc), fallopian tube cancer, primary peritoneal cancer patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer following platinum-based chemotherapy measurable lesions (according to recist 1.1 criteria, non-lymph node lesions ct scan long diameter ≥ 10 mm, lymph node lesions ct scan short diameter ≥ 15 mm) ecog ps score: 0 - 1; exclusion criteria: * subject has prior or concurrent other malignancy prior treatment with other pd-l1/pd-l1 inhibitors cannot be enrolled; subject has known previous hypersensitivity to macromolecular protein preparations or applied drug components
telephonic contact and subsequent physical follow up treated lung cancer patients

Conditions: Lung Cancer

Summary: does the routine clinical practice of follow up after primary treatment in lung cancer patients has any utility.

patients of cancer, after their primary treatment are subsequently called for follow up visits to assess the disease status. this has two important implications from the point of view of resource management. one, patients often have to travel long distances to report to the hospital and have to take care of other logistics such as their accommodation, local travel and food. further often the patient travels with 1-2 attendants which adds to the logistic burden. also, these patients of follow up also contribute to the load on existing hospital services. many authors have speculated that follow-up visits generate anxiety about possible disease recurrence. on the other hand, many others have suggested that although there may be a transient increase in anxiety, patients are ultimately reassured by this practice. hence, there is no firm evidence for the practice and the need for follow up in oncology care.

Eligibility criteria:
inclusion criteria: 1. all patients of lung cancer treated with a radical aim (e.g surgery, chemoradiation, surgery followed by adjuvant treatment or any other combination) 2. patients should have completed radical /adjuvant treatment, if any 3. patients of both sclc and nsclc 4. patients with at least two telephone numbers (landline/mobile/both) 5. patients willing to participate exclusion criteria: 1. all patients for palliative intention 2. patients with less than two contact telephone numbers -

Keywords: lung cancer followup physical follow up telephonic followup
transfusion in adult acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: acute myeloid leukaemia (aml) is a haematological malignant disease characterized by an uncontrolled proliferation of immature hematopoietic cells. over the last two decades, clinical trials have demonstrated an improved response rate in younger adult aml. aggressive induction plus more potent intensification programs with chemotherapy alone or chemotherapy plus stem cell transplantation (sct) has improved treatment results. advances in understanding disease biology, improvements in induction and consolidation program, and better supportive care have also all contributed. a number of clinical and laboratory characteristics influence the response to treatment and, thus, the survival of patients with aml. among them, cytogenetic at diagnosis represents the most important prognostic variable. however, other factors may have a prognostic value and may influence patient's outcome. anaemia and thrombocytopenia are cardinal manifestations of aml. over the last decades, it has become apparent that the frequency of allogeneic blood transfusions can modify host immunity and clinical outcomes. anaemia has long been recognized as an adverse prognostic factor in myelodysplastic syndrome (mds), which represents a pre-leukemic disease. red blood cell (rbc) transfusion need was identified as a strong and independent risk factor for survival in mds, for which the presence and severity of anaemia were attributed to a clonally advanced and biologically more aggressive disease. based on these data, we retrospectively assessed the prognostic value of rbc and platelet transfusions at the time of diagnosis and the frequency of transfusions during the first induction course of chemotherapy in a large unselected group of patients with previously untreated aml.


Eligibility criteria:
inclusion criteria: * patient \> 15 years old * newly diagnosed aml or post myelodysplastic syndrome (mds) exclusion criteria: * patients with m3 aml of fab classification (apl, acute promyelocytic leukemia) * world health organization (who) performance status \>2; * left ventricular systolic ejection fraction below the normal range * patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study * serum creatinine concentration \> 2x uln (upper limit of normal laboratory ranges), * ast or alt levels \> 2.0 x uln, except if aml-related

Keywords: transfusion dependency transfusion intensity prognosis chemotherapy
propranolol, carvedilol and rosuvastatin in the prevention of variceal bleeding in cirrhotic portal hypertension

Conditions: Cirrhosis; Portal Hypertension; Variceal Hemorrhage

Summary: patients with hepatic cirrhosis and previous variceal bleeding will be randomly assigned to use propranolol or carvedilol. after 8 weeks, rosuvastatin or placebo will be blindly added to nonresponders (hvpg measurement \> 12mmhg) for another 8 weeks and hemodynamic response will be assessed again. surrogate serum markers of portal hypertension will be evaluated and correlated to hvpg values and to its variations.


Eligibility criteria:
inclusion criteria: * hepatic cirrhosis of any etiology * previous variceal bleeding * endoscopic variceal eradication at least 2 weeks before exclusion criteria: * beta blocker or statin contraindications * model for end-stage liver disease (meld) score \> 25 * child-pugh score \> 13 * hvpg ≤ 12 mmhg * creatinine clearance \< 50 ml/min * refractory ascites * hepatic encephalopathy stages 3 or 4 * alcohol use in the last 6 months * hepatitis c treatment in the last 6 months * changing or initiating a new hepatitis b treatment in the last 6 months * malignant neoplasms from any origin except basal cell carcinoma * hiv infection * pregnancy * anticoagulation * recent or complete portal vein thrombosis
flowtriever for acute massive pulmonary embolism (flame)

Conditions: PE - Pulmonary Embolism; PE - Pulmonary Thromboembolism

Summary: to evaluate treatment outcomes of patients diagnosed with high-risk (massive) pulmonary embolism


Eligibility criteria:
inclusion criteria: age \>=18 years treatment team determines pulmonary embolism is the cause of shock, and the pe is high-risk per the protocol definitions exclusion criteria: * out of hospital cardiac arrest with glasgow coma scale of ≤8 * witnessed cardiac arrest with ongoing cpr \>30 minutes * contraindication to anticoagulants, i.e. heparin or alternative * hematocrit \<28% * platelets \<25,000/μl * inr \>8 * intracardiac thrombus and/or intracardiac clot in transit * known anaphylactic sensitivity to radiographic agents that cannot be pre-treated * history of pulmonary hypertension with systolic pulmonary arterial pressure \>70 mmhg * presence of chronic medical conditions with estimated \< 90 days life expectancy per physician discretion (should not consider the current pulmonary embolism and its treatment) * current participation in another drug or device treatment study that, in the investigator's opinion, would interfere with participation in this study * patient is known to be covid-19 positive at hospital admission (patient has active covid-19)

Keywords: pe pulmonary embolism thromboembolism thrombectomy flowtriever massive pulmonary embolism high risk pulmonary embolism
biomarkers of traumatic brain injury spain (biotrabis)

Conditions: Mild Traumatic Brain Injury; Moderate Traumatic Brain Injury

Summary: traumatic brain injury (tbi) is defined as a structural alteration of brain function caused by external causes, where mild traumatic brain injury (mtbi) represents approximately 80% of all tbi, and although its prognosis is relatively good, it represents a significant cost to the system due to the need to perform a cranial computed tomography (ct) scan, a test of high economic value and not without risks such as irradiation, especially important and dangerous in the pediatric age. the investigators aim to set-up a point of-care (poc) device to validate a biomarker (h-fabp) able to diagnose the presence of brain damage in children and adults with mtbi at trauma and paediatric emergency departments using a blood sample, in order to save resources and avoid subjecting patients to a potentially damaging imaging test. but also, to assess whether the incorporation of new biomarkers improves the prediction of brain damage that can be done with h-fabp. for that, the investigators will recruit a 400 patients' cohort with blood samples using the available poc device for h-fabp biomarker.


Eligibility criteria:
biotrabis\>18 (adult patients) inclusion criteria: * patients over 18 years old * mild tbi patients the first 24 hours after trauma with gcs of 14-15 points. * presence of any of the following symptoms: * loss of consciousness less than 30 minutes, the first 20 minutes after trauma * post-traumatic amnesia less than 24 hours, the first 30 minutes after trauma: * persistent headache * nausea / vomiting * vertigo / dizziness * confusion / disorientation exclusion criteria: * recent history (\<1 month) of tbi * refusal to participate in the study * evidence of alcohol or other substance intoxication * epilepsy * schizophrenia biotrabis\<18 (paediatric patients) inclusion criteria: * patients between 0 and 17 years old. * mild tbi (gcs 14-15) and moderate tbi (gcs 9-13) patients the first 24 hours after trauma. * presence of any of the following symptoms: * loss of consciousness less than 30 minutes, the first 20 minutes after trauma * post-traumatic amnesia less than 24 hours, the first 30 minutes after trauma: * persistent headache * nausea / vomiting * vertigo / dizziness * confusion / disorientation exclusion criteria: * recent history (\<1 month) of tbi * refusal to participate in the study * evidence of alcohol or other substance intoxication * epilepsy * schizophrenia